Samyang Biopharm삼양바이오팜
0120G0 · KOSPI · ₩0120G0 · 삼양바이오팜
₩42,000▼ ₩300 (0.71%)End-of-day · Oct 27, 2026 · End-of-day prices.
Income statement
| Q2 2026 | Q1 2026 | |
|---|---|---|
| Revenue | ₩36B | ₩31B |
| Cost of sales | ₩20B | ₩16B |
| Gross profit | ₩16B | ₩15B |
| Operating income | ₩746M | ₩1.4B |
| Net income | ₩1.3B | ₩2.6B |
| Net income to shareholders | ₩1.3B | ₩2.6B |
Balance sheet
| Q2 2026 | Q1 2026 | |
|---|---|---|
| Total assets | ₩277B | ₩353B |
| Current assets | ₩105B | ₩186B |
| Cash and equivalents | ₩17B | ₩36B |
| Total liabilities | ₩38B | ₩116B |
| Current liabilities | ₩21B | ₩99B |
| Borrowings | ₩14B | ₩90B |
| Total equity | ₩239B | ₩237B |
| Shareholders' equity | ₩239B | ₩237B |
Cash flow
| Q2 2026 | Q1 2026 | |
|---|---|---|
| Cash from operations | ₩5.7B | ₩5.2B |
| Capital spending | ₩10B | ₩983M |
| Free cash flow | −₩4.3B | ₩4.2B |
Consolidated where available. Amounts in won.
Also known as: Samyang Biopharm / 삼양바이오팜 / 0120G0 / KRX:0120G0
Source: KRX statistical information